GREY:ATBPF - Post by User
Comment by
Actuarialon Jun 04, 2021 2:37pm
100 Views
Post# 33331141
RE:nosh
RE:nosh If you have reviewed Avicenna pipeline, you would understand why NOSH is not a competition to ATE yet. And if you Google the details of NOSH patent, you will see a name Wallace in the reference. Ha, NOSH might be a competition someday. However, the someday is far far away as Avicenna has nothing serious yet . And their patents rely on ATE platform. Even they might have something better, they have to wait for h2s patents expiring and exclusive right expires. We have enough time to harvest investment.
Nick80 wrote: Hi what are you guys think about:
https://www.avicennatherapeutics.com/technology
Would they be serious competition for ate 346, 352 or 340?
From my understanding their platform might outperform ATE's 340 drug if successful, however what about 346 and others?
Their nosh platform is in pre-clinical only meaning ate is very well advanced and derisked compared to them...